Senseonics Q3 ’18 Earnings Update; Abbott FreeStyle Link Now Available

Senseonics hosted its Q3 ’18 earnings call and provided updates on the Eversense implantable CGM launch as well as pipeline activities. Additionally, Abbott recently announced the approval of Libre Link, an app that allows users to scan the Libre device with their iPhone. Below, FENIX provides thoughts on the Eversense launch, ongoing negotiations with Roche, and the potential impact of the Libre Link to accelerate Libre adoption.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.